In this episode of The Oncology Insights Podcast, I speak with Dr. Stephen Nimer, Director of the Sylvester Comprehensive Cancer Center at the University of Miami. We explore his remarkable journey from physician-scientist to national leader in hematologic oncology, focusing on acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). We also discuss cellular therapy, precision medicine, and the challenges of translational research in today’s oncology landscape. Listen now on all major platforms! “Understanding the interplay between leukemia cells and their microenvironment is essential to identifying effective new therapeutic targets.” Meet the guest: Dr. Stephen Nimer https://www.linkedin.com/in/stephen-nimer-4a407022/ is the Director of the Sylvester Comprehensive Cancer Center and Executive Dean for Research at the University of Miami Miller School of Medicine. A leading physician-scientist in hematology-oncology, his research focuses on myelodysplastic syndromes and acute myelogenous leukemia, advancing translational science and patient care. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:45) Introduction (12:59) AML treatment challenges (23:22) MDS overview (30:17) Animal research ethics (33:32) Leadership strategy (37:14) Precision medicine (38:52) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/

In this episode of The Oncology Insights Podcast, Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, shares results from the global MATTERHORN study and what it means for early-stage gastroesophageal cancer treatment. She explains how immunotherapy is shifting the treatment landscape, the real-world challenges of biomarker access, and why surgical collaboration matters. Listen now on all major platforms! "Despite aggressive chemotherapy regimens, the addition of immunotherapy showed improvement in survival and disease-free outcomes." Meet the guest: Dr. Yelena Janjigian https://www.linkedin.com/in/yelena-janjigian-702123100/ is a physician-scientist and Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. Her research focuses on the molecular characterization of gastroesophageal cancers, aiming to bring innovative therapies to patients worldwide. With over 140 publications, she is a global leader in GI oncology. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:52) Introduction (07:46) Immunotherapy in early-stage (10:26) Trial design challenges (15:03) Regional cancer differences (19:00) Tumor biomarker limitations (24:11) Surgery coordination issues (27:29) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/

In this episode of The Oncology Insights Podcast, Dr. Thomas Marron, Director of the Early Phase Trials Unit at Mount Sinai, explains how immunotherapy has reshaped cancer treatment. He discusses checkpoint inhibitors, cancer vaccines, cellular therapies, and the challenges of early-onset cancers. Learn how inflammation and aging impact immune response and what innovations are on the horizon. Listen now on all major platforms! "Tumors often contain more immune cells than cancer cells, highlighting how critical immune dysfunction is in cancer development." Meet the guest: Dr. Thomas Marron https://www.linkedin.com/in/thomas-marron-8969a252/ is Director of the Early Phase Trials Unit at Mount Sinai and a Professor of Medicine, Hematology, and Immunotherapy. With both an MD and PhD in Immunology, his research focuses on novel cancer immunotherapies and personalized vaccine strategies. He leads clinical trials that explore immune mechanisms and tumor biology in solid tumors. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:43) Introduction (01:57) Checkpoint inhibitor evolution (12:41) Cancer vaccine development (16:25) CAR-T therapy limits (20:01) Role of inflammation (25:38) Early-onset cancer trends (29:43) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/oncologyinsights Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/

I’m Dr. Steven Rosen, and I am pleased to introduce the first episode of The Oncology Insights Podcast. This podcast is created for professionals dedicated to advancing cancer care. In the episodes ahead, I’ll be joined by Dr. Abbie Begnaud, Associate Professor of Pulmonary and Critical Care at the University of Minnesota, and Dr. William Oh, Director of Precision Medicine at Yale Cancer Center and Smilow. Together, we will examine the latest research and essential topics that are shaping the future of oncology. In this episode of The Oncology Insights Podcast, Dr. Joseph Mikhael, Professor at TGen and Chief Medical Officer of the International Myeloma Foundation, explores the evolving landscape of multiple myeloma care. He discusses optimal drug regimens, immunotherapies, health disparities, and the promise of MRD testing and early intervention. Understand how cutting-edge strategies are extending and improving patient lives. Listen now on all major platforms! “The vast majority of patients treated with multiple myeloma today as their initial therapy should receive a quadruple.” Meet the guest: Dr. Joseph Mikhael https://www.linkedin.com/in/joseph-mikhael-8432188/ is Professor at the Translational Genomics Research Institute and Chief Medical Officer of the International Myeloma Foundation. With extensive expertise in plasma cell disorders, his work focuses on advancing clinical research, patient education, and addressing disparities in multiple myeloma care. What you will learn: (00:00) Highlight (00:38) Introduction (12:38) Quadruplet therapy today (21:39) Car-T outcomes (24:42) Bispecifics in treatment (33:38) Bone health support (34:38) Early intervention debate (38:50) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/oncologyinsights Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/